The following is a good start but if fatality rate
Post# of 714
(Total Views: 262)
Posted On: 04/29/2020 3:12:18 PM
The following is a good start but if fatality rates stay at this level there will be a significant need for more effective treatments and vaccines IMO.
=================================
Fauci gives his blessing to remdesivir
Apr. 29, 2020 12:22 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Stephen Alpher, SA News Editor
The result from Gilead's (NASDAQ:GILD) trial of remdesivir is "quite good news," says "President" Anthony Fauci, with the data showing "clear cut significant positive effect in diminishing the time to recovery." The FDA, he says, is working with Gilead on the availability of the drug.
The Chinese study (negative results leaked last week, and details published this morning) was "underpowered, not adequate," says Fauci.
Fauci's comments seem to have put an extra charge into GILD - shares are now up 7% for the session.
CNBC's Meg Tirrell has details shared by Fauci on the more-important NIAID trial:
The primary endpoint was time to improvement, with those on remdesivir showing that in 11 days, and those on placebo 15 days.
The mortality rate on remdesivir was 8% vs. 11% for those on placebo.
Update: Dr. Fauci says the randomized, placebo-controlled study enrolled ~1,090 patients. The primary endpoint was the time to recovery and the ability to be discharged from the hospital. The independent Data Monitoring Committee informed him that remdesivir's clinical benefit was "clear-cut" and highly statistically significant (p<0.001). The drug's mortality benefit, while numerically better, is not yet statistically significant. Remdesivir represents a new standard-of-care for COVID-19. Studies testing remdesivir combined with other meds are next up.
=================================
Fauci gives his blessing to remdesivir
Apr. 29, 2020 12:22 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Stephen Alpher, SA News Editor
The result from Gilead's (NASDAQ:GILD) trial of remdesivir is "quite good news," says "President" Anthony Fauci, with the data showing "clear cut significant positive effect in diminishing the time to recovery." The FDA, he says, is working with Gilead on the availability of the drug.
The Chinese study (negative results leaked last week, and details published this morning) was "underpowered, not adequate," says Fauci.
Fauci's comments seem to have put an extra charge into GILD - shares are now up 7% for the session.
CNBC's Meg Tirrell has details shared by Fauci on the more-important NIAID trial:
The primary endpoint was time to improvement, with those on remdesivir showing that in 11 days, and those on placebo 15 days.
The mortality rate on remdesivir was 8% vs. 11% for those on placebo.
Update: Dr. Fauci says the randomized, placebo-controlled study enrolled ~1,090 patients. The primary endpoint was the time to recovery and the ability to be discharged from the hospital. The independent Data Monitoring Committee informed him that remdesivir's clinical benefit was "clear-cut" and highly statistically significant (p<0.001). The drug's mortality benefit, while numerically better, is not yet statistically significant. Remdesivir represents a new standard-of-care for COVID-19. Studies testing remdesivir combined with other meds are next up.
(2)
(0)Scroll down for more posts ▼